Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
DC
First Claim
Patent Images
1. A pharmaceutical composition comprising:
- (a) a compound selected from aripiprazole or a metabolite of aripiprazole, wherein the metabolite of aripiprazole is selected from the group consisting of dehydroaripiprazole, DM-1451 and DM-1452 in combination with(b) at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram, and salts thereof.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
40 Citations
32 Claims
-
1. A pharmaceutical composition comprising:
-
(a) a compound selected from aripiprazole or a metabolite of aripiprazole, wherein the metabolite of aripiprazole is selected from the group consisting of dehydroaripiprazole, DM-1451 and DM-1452 in combination with (b) at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram, and salts thereof. - View Dependent Claims (5, 6, 7, 8, 9)
-
- 2. A pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlaflaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline and salts thereof.
-
3. A pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from escitalopram or a salt thereof.
- 10. A pharmaceutical composition comprising at least one metabolite of aripiprazole selected from the group consisting of dehydroaripiprazole, DM-1451 and DM-1452 in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.
-
17. A method of treating a mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression incombination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer'"'"'s type with depressive symptoms, Parkinson'"'"'s disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising:
- administering to the patient an effective amount of a pharmaceutical composition which comprise(s) (a) a compound selected from aripiprazole or metabolite of aripiprazole wherein the metabolite of aripiprazole is selected from the group consisting of dehydroaripiprazole, DM-1451 and in combination with (b) at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram, and salts thereof.
- View Dependent Claims (21, 22, 23, 24, 25)
-
18. A method of treating a mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer'"'"'s type with depressive symptoms, Parkinson'"'"'s disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising:
- administering to the patient an effective amount of a pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline and salts thereof.
- View Dependent Claims (20)
-
19. A method of treating mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer'"'"'s type with depressive symptoms, Parkinson'"'"'s disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising:
- administering to the patient of an effective amount of a pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from escitalopram and salt thereof.
-
26. A method of treating a mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer'"'"'s type with depressive symptoms, Parkinson'"'"'s disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising:
- administering to the patient of an effective amount of pharmaceutical composition comprising at least one metabolite of aripiprazole selected from the group consisting of dehydroaripiprazole, DM-1451 and DM-1452 DM in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.
- View Dependent Claims (27, 28, 29, 30, 31, 32)
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeOtsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
-
Original AssigneeOtsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
-
InventorsKikuchi, Tetsuro, Iwamoto, Taro, Hirose, Tsuyoshi
-
Primary Examiner(s)RAO, SAVITHA M
-
Application NumberUS14/252,907Publication NumberTime in Patent Office819 DaysField of SearchUS Class Current1/1CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/135 having aromatic rings , e.g...A61K 31/137 Arylalkylamines, e.g. amphe...A61K 31/138 Aryloxyalkylamines, e.g. pr...A61K 31/15 Oximes (>C=N—O—); Hydrazine...A61K 31/165 having aromatic rings, e.g....A61K 31/343 condensed with a carbocycli...A61K 31/381 having five-membered ringsA61K 31/4525 containing a five-membered ...A61K 31/496 Non-condensed piperazines c...A61P 25/18 Antipsychotics, i.e. neurol...A61P 25/24 AntidepressantsA61P 25/28 for treating neurodegenerat...
